These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12575618)

  • 61. Safety and tolerability of combination antiretroviral post-exposure prophylaxis in a population-based setting.
    Braitstein P; Chan K; Beardsell A; McLeod A; Montaner JS; O'Shaughnessy MV; Hogg RS
    J Acquir Immune Defic Syndr; 2002 Apr; 29(5):547-8. PubMed ID: 11981375
    [No Abstract]   [Full Text] [Related]  

  • 62. The abacavir hypersensitivity reaction: a review.
    Clay PG
    Clin Ther; 2002 Oct; 24(10):1502-14. PubMed ID: 12462283
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Efavirenz decreases methadone blood concentrations.
    Marzolini C; Troillet N; Telenti A; Baumann P; Decosterd LA; Eap CB
    AIDS; 2000 Jun; 14(9):1291-2. PubMed ID: 10894303
    [No Abstract]   [Full Text] [Related]  

  • 64. How do abacavir and efavirenz differ in pharmacokinetics and toxicity?
    Edmunds-Ogbuokiri J
    Fac Notes (New Orleans La); 1999; 11(3):1-4. PubMed ID: 11810867
    [No Abstract]   [Full Text] [Related]  

  • 65. Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy.
    García-Benayas T; Blanco F; de la Cruz JJ; Soriano V; González-Lahoz J
    AIDS; 2003 Apr; 17(6):921-4. PubMed ID: 12660543
    [No Abstract]   [Full Text] [Related]  

  • 66. [Use of antiretroviral drugs in HIV infected children in a tropical area: a real benefit].
    Timité-Konan AM; Fassinou P; Adonis-Koffy L; N'dja BB
    Arch Pediatr; 2003 Sep; 10(9):831-2. PubMed ID: 12972212
    [No Abstract]   [Full Text] [Related]  

  • 67. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.
    Hetherington S; McGuirk S; Powell G; Cutrell A; Naderer O; Spreen B; Lafon S; Pearce G; Steel H
    Clin Ther; 2001 Oct; 23(10):1603-14. PubMed ID: 11726000
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity.
    Frissen PH; de Vries J; Weigel HM; Brinkman K
    AIDS; 2001 Jan; 15(2):289. PubMed ID: 11216946
    [No Abstract]   [Full Text] [Related]  

  • 69. The abacavir hypersensitivity reaction and interruptions in therapy.
    Loeliger AE; Steel H; McGuirk S; Powell WS; Hetherington SV
    AIDS; 2001 Jul; 15(10):1325-6. PubMed ID: 11426085
    [No Abstract]   [Full Text] [Related]  

  • 70. Individualising HIV treatment--pharmacogenetics and immunogenetics.
    Telenti A; Aubert V; Spertini F
    Lancet; 2002 Mar; 359(9308):722-3. PubMed ID: 11888578
    [No Abstract]   [Full Text] [Related]  

  • 71. Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients.
    Negredo E; Ribalta J; Ferré R; Salazar J; Rey-Joly C; Sirera G; Masana L; Clotet B
    AIDS; 2004 Mar; 18(5):819-21. PubMed ID: 15075521
    [No Abstract]   [Full Text] [Related]  

  • 72. Agranulocytosis and fever seven weeks after starting abacavir.
    Sankatsing SU; Prins JM
    AIDS; 2001 Dec; 15(18):2464-5. PubMed ID: 11774836
    [No Abstract]   [Full Text] [Related]  

  • 73. Anaphylaxis after rechallenge with abacavir.
    Walensky RP; Goldberg JH; Daily JP
    AIDS; 1999 May; 13(8):999-1000. PubMed ID: 10371187
    [No Abstract]   [Full Text] [Related]  

  • 74. Unusual clinical presentation of hypersensitivity reaction to abacavir.
    Aquilina C; Mularczyk M; Lucas F; Viraben R
    AIDS; 2003 Nov; 17(16):2403-4. PubMed ID: 14571198
    [No Abstract]   [Full Text] [Related]  

  • 75. Reversal of AIDS dementia after combination therapy with stavudine, lamivudine, and nelfinavir.
    Mastroianni CM; Trinchieri V; Santopadre P; Lichtner M; Forcina G; D'Agostino C; Dell'Isola S; Vullo V
    J Neurol; 1999 Oct; 246(10):972-3. PubMed ID: 10552250
    [No Abstract]   [Full Text] [Related]  

  • 76. Remission of HIV myelopathy after highly active antiretroviral therapy.
    Staudinger R; Henry K
    Neurology; 2000 Jan; 54(1):267-8. PubMed ID: 10636172
    [No Abstract]   [Full Text] [Related]  

  • 77. Abacavir warning.
    AIDS Patient Care STDS; 2000 Nov; 14(11):617. PubMed ID: 11155904
    [No Abstract]   [Full Text] [Related]  

  • 78. Abacavir sulfate and mania in HIV.
    Brouilette MJ; Routy JP
    Am J Psychiatry; 2007 Jun; 164(6):979-80. PubMed ID: 17541065
    [No Abstract]   [Full Text] [Related]  

  • 79. Human genetic variability and HIV treatment response.
    Haas DW
    Curr HIV/AIDS Rep; 2006 Jul; 3(2):53-8. PubMed ID: 16608660
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Report from the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. HLA B-5701 and abacavir hypersensitivity.
    Albrecht H
    AIDS Clin Care; 2007 Oct; 19(10):81-2. PubMed ID: 18398994
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.